TECregen

Basel, Switzerland

TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.

$12.5M raised

Jan 2026

Seed

Biotechnology Manufacturing Product Research

Top Investors

HTGF (High-Tech Gruenderfonds)Boehringer Ingelheim Venture FundZürcher Kantonal BankCarma FundLifespan Vision Ventures

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about TECregen

How much funding has TECregen raised?

TECregen has raised $12.5M in total funding. The most recent round was Seed. The last funding was announced in January 2026.

Who are TECregen's investors?

TECregen's investors include HTGF (High-Tech Gruenderfonds), Boehringer Ingelheim Venture Fund, Zürcher Kantonal Bank, Carma Fund, Lifespan Vision Ventures.

Where is TECregen headquartered?

TECregen is headquartered in Basel, Switzerland.

What does TECregen do?

TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.

What stage is TECregen at?

TECregen is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 8, 2026.

MLA

"TECregen — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/tecregen. Accessed July 1, 2026.

APA

VCBacked. (2026). TECregen — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/tecregen

Wikipedia (cite web)

{{cite web |title=TECregen — Funding & Investors |url=https://www.vcbacked.co/company/tecregen |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 8, 2026.

Similar Companies in Biotechnology

View all

Renaissance BioScience

Vancouver$599K

Allterum Therapeutics

Advanced Microbiome Interventions

Amsterdam$300K